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Cardiovascular consequences of correction of the anemia of renal
failure with erythropoietin. The purpose of this study was to define the
physiologic responses of the heart and peripheral circulation to chronic
anemia using noninvasive measurements while eliminating confounding
biochemical, pharmacologic and physiologic variables. Stable chronic
hemodialysis patients were studied at the University Hospital based
chronic dialysis unit and echocardiography laboratory before and after
therapy with human recombinant erythropoietin (rHuEPO). Subjects
included maintenance hemodialysis patients free of left ventricular
regional wall motion abnormalities discernible by echocardiography,
rhythm disturbance, significant valvular or ischemic heart disease.
Two-dimensional echocardiograms and simultaneous targeted M-mode
echocardiograms, phonocardiograms and externally acquired subcla-
vian artery pulse tracings were used to measure whole blood viscosity,
arterial blood gases and ionized calcium, complete blood count, elec-
trolytes, creatinine, blood urea nitrogen (BUN), and inorganic phos-
phate. All measurements were made immediately post-dialysis before
and after therapy with rHuEPO. The interval between pre- and post-
rHuEPO studies was 8.3 2.3 months. We found that post-dialysis
hematocrit rose from 24.7 0.9 to 36.4 0.9%, hemoglobin from 83
3 to 121 3 g/liter and whole blood viscosity from 2.87 0.11 to 3.71
0.18 centipoise (all, P < 0.001 after therapy with rHuEPO). The
remaining biochemical measurements did not change. Heart rate fell
from 83 3 to 77 3 beats/mm (P = 0.013). Left ventricular preload
and afterload were not statistically different before and after rHuEPO.
Total vascular resistance rose from 1313 84 to 1568 129
dynes sec cm5, P = 0.029. Cardiac output and cardiac index fell by
12 and 15% (P = 0.024 and 0.030), respectively. Left ventricular
contractility assessed using load and heart rate independent indices fell
after therapy with rHuEPO (P = 0.003) in the nine patients in whom it
was measured. In conclusion, correction of the anemia of chronic renal
failure in maintenance hemodialysis patients with rHuEPO reduces
measurements of global left ventricular systolic function by decreasing
the heart rate and contractile state without significantly altering cham-
ber loading conditions. The net effect is a decrease in the hyperdynamic
circulatory state that typically characterizes chronic anemia.
The mechanisms by which the cardiovascular system com-
pensate for the reduced oxygen carrying capacity of chronic
anemia have been a topic of investigation and controversy for
nearly half a century. Studies performed in animals made
anemic by infusion of high and low molecular weight dextran [1,
21 and in humans with renal failure who received blood trans-
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fusions [3] proposed that anemia is a hyperdynamic circulatory
state characterized by increased cardiac output, stroke volume,
preload and contractility. Further support for this premise came
from investigations of cardiovascular physiology in patients
whose anemia was alleviated alter kidney transplantation [4, 5].
Interpretation of the results of these studies, however, is
impeded by intra- and inter-patient differences in blood pres-
sure, biochemical milieu and drugs.
The recent introduction of human recombinant erythropoie-
tin (rHuEPO) into clinical medical practice has provided a
unique opportunity to study the hemodynamic and cardiovas-
cular responses to the correction of the anemia of renal failure.
However, contemporary studies of dialysis patients treated
with rHuEPO have employed models that often make mecha-
nistic interpretation of the cardiovascular changes associated
with this therapy difficult. Specifically, changes in blood ionized
calcium (Ca2), potassium or pH, use of beta adrenoreceptor or
calcium entry channel blocking drugs, or alterations in heart
rate and loading conditions can influence myocardial perfor-
mance and consequently, when not tightly controlled, generate
conflicting results. For example, Verbeelen et al [6] and Paga-
nini et al [7] reported an improvement in cardiac output (CO)
and a fall in total vascular resistance (TVR) alter improvement
of anemia with rHuEPO. In contrast, other investigators utiliz-
ing a variety of protocols and techniques for measuring hemo-
dynamic variables, found a fall in cardiac index and an increase
in systemic vascular resistance [8—15]. Myocardial contractility
has been reported to improve [10, 13] or not change [9].
Progressive myocardial dysfunction occurs in the majority of
patients undergoing long—term dialysis [16—20]. The extent to
which the increased myocardial work and energetic demands
associated with a hyperdynamic circulatory state contributes to
this cardiomyopathy is unclear. The purpose of the current
prospective study was to define the physiologic responses of the
heart and peripheral circulation to chronic anemia using nonin-
vasive measurements of left ventricular loading conditions and
contractile state while eliminating confounding biochemical,
pharmacologic [21] and physiologic variables; only red cell
mass and whole blood viscosity changed over time. In this
manner it was possible to test the hypothesis that amelioration
of chronic anemia in patients with renal failure lessens a
hyperdynamic circulatory state by decreasing ventricular load-
ing conditions and contractile state. The net result of these
changes would be a decrement in myocardial work.
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Methods
Patients
The current investigation consisted of 18 stable hemodialysis
patients (13 female and 5 male) ranging in age from 21 to 68 (45
4) years who had technically adequate ultrasound images.
Causes of end-stage renal disease were nephrosclerosis (6
patients), lupus nephritis (4 patients), diabetic nephropathy (3
patients), glomerulonephritis (2 patients) chronic interstitial
nephritis (1 patient) and polycystic kidney disease (1 patient).
Duration of hemodialysis was 10 to 124 months (mean 40 19
months). No study patient had regional wall motion abnormal-
ities on two-dimensional echocardiographic examination, car-
diac rhythm disturbances or a history of ischemic heart disease
or clinically significant valvular heart disease. None had taken
beta adrenoreceptor or calcium channel blocking agents or
positive inotropic drugs within one week of the study day. None
experienced intercurrent illness or change in biochemical con-
trol during the study period. All patients had a predialysis
hematocrit of 25% or less. Thirty-one patients were originally
entered into the study; thirteen failed to complete the protocol
because of death (2 patients), renal transplantation (4 patients),
intercurrent illness (3 patients), development of myocardial
ischemia (2 patients) or refusal to participate in the second
study (2 patients).
rHuEPO administration
rHuEPO (AMGEN, Thousand Oaks, California, USA), ap-
proximately 50 U/kg body wt, was administered to each patient
through the dialysis venous line at the end of each dialysis until
the hematocrit achieved a stable prehemodialysis level of
30%. Thereafter, the dose of rHuEPO was adjusted to main-
tain this value. Iron stores were assessed monthly and iron
supplementation was provided with parenteral iron dextran
(Imferon, Fissons) or oral iron in patients who had demon-
strated hypersensitivity to iron dextran.
Study conditions
Immediately after a regular hemodialysis and ultrafiltration
utilizing bicarbonate dialysate, blood was drawn from the
arterial limb of the dialysis fistula for biochemical measure-
ments and blood gases. Thus, all blood values reflected the
immediacy of dialysis and ultrafiltration. Cardiovascular studies
were always performed within two hours of dialysis in order to
ensure constancy of the biochemical milieu and isovolemia. We
have reported previously on the high level of hemodynamic and
biochemical stability achieved during this initial post-dialysis
period [22]. Blood determinations were made in the clinical
chemistry and pulmonary function laboratories of the Univer-
sity of Chicago Medical Center. Blood viscosity was measured
with a cone plate viscometer (Wells-Brookfield, model LVT-
DV2, Stoughton, Massachusetts, USA). The interval between
pre- and post-rHuEPO studies was 8.3 2.3 months. Patients
maintained a stable predialysis hematocrit of 30% or more for at
least two months before the second study was performed.
In order to assess the effect of therapy with rHuEPO on blood
pressure, pre- and post-dialysis weights and blood pressures
measured with a sphygmomanometer were recorded for every
dialysis for a period of at least two months prior to initiation of
therapy with rHuEPO and for at least four months after
achieving target hematocrit.
Data acquisition
Ultrasound evaluation was performed using a 2.5 MHz im-
aging transducer and a 1.9 MHz Pedof transducer (Hewlett-
Packard, Andover, Massachusetts, USA). Two-dimensional
echocardiographic images of the left ventricle were acquired
during held end-expiration using (1) a parasternal short axis
transducer position in which the ultrasound beam was directed
at the mid equatorial plane of the ventricle (that is, just off the
tip of the anterior leaflet of the mitral valve), and (2) an apical
four chamber view for determination of long axis (L) dimen-
sion. Simultaneous two-dimensionally targeted M-mode
echocardiograms, phonocardiograms and externally-acquired
subclavian artery pulse tracings were recorded in conjunction
with measurements of systemic blood pressure (Dinamap Vital
Signs Monitor, model #946P, Critikon, Inc., Tampa, Florida,
USA). The subclavian pulse tracings were calibrated such that
peak systolic blood pressure was set to the peak of the tracing
and arterial diastolic pressure to the nadir. Left ventricular
pressures at end-systole (Pes) were determined by linear inter-
polation. This method of calibration been shown previously to
be accurate for a wide range of ejection pressures and cardiac
outputs [23].
In order to assess cardiac performance over a range of left
ventricular loading conditions, recordings were obtained under
control conditions as well as during infusion of either the
alpha,-specific adrenoreceptor agonist methoxamine or the
vasodilator nitroprusside. Methoxamine (1 mg/mm), which was
used when baseline mean arterial pressure was 125 mm Hg or
less, caused an increase in left ventricular systolic pressure
secondary to peripheral vasoconstriction without effects on
ventricular contractile state. Heart rate was maintained within a
narrow range with atropine sulfate (0.005 to 0.010 mg/kg body
wt). The ventricular response to arterial vasoconstriction was
assessed with recordings obtained every one to two minutes
until peak systolic pressure had increased 20 to 40 mm Hg
above baseline. At that time infusion of methoxamine was
discontinued. The peak pressor effect lasted two to five min-
utes. Nitroprusside was given if baseline mean arterial pressure
was greater than 125 mm Hg. The infusion rate was titrated
incrementally from 0.125 to 2.0 gJkg/min until peak systolic
pressure fell by 10 to 20 mm Hg from the baseline values or
heart rate increased by 10 beats per minute. A control data
point as well as two to four additional points were obtained
during either the methoxamine or nitroprusside infusions.
Data analysis
Left ventricular end-systolic and end-diastolic minor and long
axis dimensions Ded, Les, Led, respectively) as well as
wall thickness (hes, had) were measured from the echocardio-
graphic recordings as described previously [221. The left ven-
tricular percent fractional shortening (%D) was calculated as
(Ded — D5)/D. The left ventricular ejection time (ET) was
measured from the subclavian pulse tracing. The rate-corrected
mean velocity of fiber shortening (Vcf) was calculated as:
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El
Vcf =
where RR equals the interval between cardiac cycles deter-
mined from the electrocardiogram. Left ventricular circumfer-
ential end-systolic wall stress (o-) was calculated using the
formula:
es = [Pressure][Geometric factor]
Des / Des3
[Pes] —
2(D5 + hes)) (1.35)h.Les
where °es is in g/cm; Pes is in mm Hg; Des, Les and hes are in cm;
and 1.35 is a conversion factor. Previous studies using this
integrated noninvasive approach to data analysis have shown
minimal inter- and intra-observer variability [24].
Left ventricular contractile state was assessed using the heart
rate and load-independent relationship between circumferential
end-systolic wall stress and rate-corrected velocity of fiber
shortening (°es — Vcf). This relationship was determined by
linear regression analysis (least squares method) using a mini-
mum of three data points acquired over a range of left ventric-
ular loading conditions generated by either methoxamine or
nitroprusside. Comparisons of °es — Vcf data obtained pre-
and post-rHuEPO therapy were made by the determination of
Vcf values at a common level of end-systolic circumferential
wall stress. The midpoint of the region of overlap for these two
lines was selected as the point of afterload (that S, °es)
commonality. The difference in Vcf values (Vcf) was calcu-
lated as Vcf (pre) minus Vcf (post). Patients were excluded
from this analysis if: (1) the heart rate changed by more than 10
beats/mm during nitroprusside or methoxamine administration,
(2) the range of circumferential end-systolic wall stress was less
than 15 g/cm2 with load manipulation, or (3) the plot of the 0es
— Vcf line obtained before and after therapy with rHuEPO did
not produce a region of overlapping data. This latter exclusion
criterion eliminated the possibility of errors due to the use of
extrapolation of data.
Left ventricular stroke volume (SV) was calculated as the
product of aortic annular cross sectional area measured by
two-dimensional echocardiography and flow velocity integral
acquired through the aortic valve using continuous wave dop-
pler. Cardiac output was calculated by multiplying the heart
rate and stroke volume. Stroke volume index and cardiac index
were calculated by dividing by body surface area. Total vascu-
lar resistance (TVR, dyne sec cm5) was determined as:
Pao
TVR = (80)
where P is mean aortic pressure (mm Hg) and CO is cardiac
output (liter/mm). Left ventricular wall mass index was calcu-
lated with the formula [25]
0.8 [1.04 (Ded + 2hed)3 — Ded3] + 0.6/body surface area
Statistics
Each patient served as his/her own control. Comparisons
were done with a paired 1-test in which P <0.05 was considered
Table 1. Summary of biochemical measurements
Variables Pre-EPO Post-EPO P value
Hemoglobin glliter 83 3 121 3 <0.001
Hematocrit % 24.7 0.9 36.4 0.9 <0.001
Sodium mmol/liter 140.4 1.2 138.9 0.6 0.25
Potassium mmol/ 3.8 0.1 3.8 0.2 0.69
liter
Blood urea nitrogen 11.6 1.5 12.5 1.0 0.56
mmol/liter urea
Creatinine pinoll 688 61 728 50 0.46
liter
Calcium mmol/liter 2.65 0.03 2.65 0.04 0.86
Phosphate mmol/ 1.1 0.07 1.2 0.07 0.46
liter
Ca2 mmol/liter 1.21 0.03 1.26 0.05 0.76
pH 7.44 0.01 7.44 0.01 0.95
p02 Torr 93 2 93 2 0.58
pCO2 Torr 37 1 37 1 0.69
Viscosity 2.87 0.11 3.71 0.18 <0.001
centipois?
Values are mean SEM.
a N 14; all other values are for N = 18 patients
statistically significant. Group data are expressed as mean
values standard error.
Results
Hematologic data
Hematocrit and hemoglobin values that defined study entry
criteria and end points were measured predialysis with regular
monthly laboratory work. However, because all blood mea-
surements obtained at the time of echocardiographic imaging
were made immediately after dialysis and ultrafiltration, hemo-
globin and hematocrit values reflected the effect of hemocon-
centration. Following treatment with rHuEPO, post-dialysis
hematocrit rose from 24.7 0.9 to 36.4 0.9% and hemoglobin
from 83 3 to 121 3 g/liter. Whole blood viscosity increased
from 2.87 0.11 to 3.71 0.18 centipoise, P <0.001 (Table 1)
in the 14 patients in whom it was measured. Hematocrits were
stable at >30% and hemoglobin >100 g/liter for at least two
months prior to acquisition of post-rHuEPO hemodynamic
measurements.
Biochemical data
Electrolytes, Ca2, phosphate, arterial blood gases, creati-
nine and blood urea nitrogen (BUN) were not different before
and after therapy with rHuEPO (Table 1).
Body weights
There were no differences in post-dialysis body weights
before or after therapy with rHuEPO (61.5 3.6 vs. 61.0 4.2
kg, P = 0.57) on the days of the echocardiographic studies.
Furthermore, pre- and post-dialysis body weights recorded for
every dialysis in the two months prior to initiation of therapy
with rHuEPO until the completion of the study did not differ
(Fig. 1).
Cardiovascular hemodynamics
The heart rate fell from 83 3 to 77 3 beats/minute, P =
0.013 (Table 2).
Arterial blood pressure during the two months prior to
1312 Fellner et a!: Cardiovascular aspects of rHuEPO treatment
Table 2. Cardiovascular hemodynamics
Variables Pre-EPO Post-EPO P value
Heart rate beats/mm 83 3 77 3 0.013
Arterial blood pressure
Peak systolic mm Hg 141 6 146 7 0.42
Diastolic mm Hg 82 5 84 5 0.61
Mean mm Hg 97 3 106 5 0.22
End systolic mm Hg 120 4 127 7 0.25
Left ventricular preload
Ded cm 4.4 0.1 4.3 0.2 0.13
Left ventricular afterload
End-systolic wall stress 136 16 144 21 0.42
9/cm2
Total vascular resistance 1313 84 1568 129 0.029
dynes sec cm5
Overall LV systolic performance
Percent fractional shortening 0.30 0.03 0.29 .03 0.42
Cardiac output liter/mitt 6.6 0.4 5.8 0.3 0.024
Cardiac index 1/mm/il 4.0 0.3 3.4 0.2 0.030
Stroke volume cm3/beat 80 4 77 4 0.51
Stroke volume index 48 3 46 2 0.45
cm2lbeatlil BSA
Left ventricular contractility
Vcf (circ/sec)a 0.96 0.07 0.85 0.07 0.003
Values are mean SEM. Abbreviations are: EPO, erythropoietin;
Ded, left ventricular end-diastolic minor axis dimension.
Vcf, rate corrected velocity of fiber shortening at a common left
ventricular afterload for 9 patients
achieving a target hematocrit of 30% was not different from that
recorded for three months thereafter. This was true for com-
parisons performed using both pre and post-dialysis values (Fig.
1). However, six of 18 patients (33%) developed interdialytic
hypertension that required a modest increase in the dose of
angiotensin converting enzyme inhibitor drugs (enalapril, lisino-
pril) or the addition of a calcium channel blocking agent
(nifedipine) to maintain normotension. The latter drug was
discontinued at least one week before echocardiographic stud-
ies, Of those who became hypertensive, four of six had renal
failure from nephrosclerosis.
Left ventricular preload, as assessed by end diastolic minor
dimensions, did not change significantly (4.4 0.1 cm to 4.3
0.2 cm, P = 0.13).
Left ventricular afterload, measured as circumferential end-
systolic wall stress (°es), was unchanged (136 16 vs. 144 21
g/cm2, P = 0.42).
Total vascular resistance rose from 1313 84
dynes sec cm5 to 1568 129 dynes sec cm5, P = 0.029.
Left ventricular wall mass index was unchanged after therapy
with rHuEPO (143 12 g/m2 vs 141 10 g/m2, P = 0.52).
Overall left ventricular systolic performance changed vari-
ably depending upon the parameter measured. Percent frac-
tional shortening, stroke volume and stroke volume index were
unchanged. However, cardiac output and cardiac index fell by
approximately 14% (P = 0.024 and 0.030, respectively) reflect-
ing, at least in part, the 7% decline in heart rate that occurred
following correction of anemia.
Left ventricular contractility was assessed in the nine pa-
tients who fulfilled the stringent criteria for determination of
Vcf at a common level of afterload. These nine patients did not
differ from the remaining nine study patients in age, etiology of
renal failure, duration of hemodialysis or medications. Three of
these nine patients and four of the remaining nine patients took
an angiotensin converting enzyme inhibitor for blood pressure
control both before and after therapy with rHuEPO. Data
obtained from one of our study patients illustrate the method by
which this relationship is used as a measurement of left ven-
tricular contractility (Fig. 2). Contractile state diminished (P =
0.003) following correction of anemia (Table 3). Figure 3
demonstrates the relationship between change in hematocrit
and change in Vcf in these nine patients.
Discussion
Our data demonstrate that correction of the anemia of
chronic renal failure with the administration of rHuEPO re-
duces measurements of global left ventricular systolic function
(such as, cardiac output) as well as contractile state. End
diastolic dimension, an index of preload, did not change signif-
icantly. This was an expected finding since these measurements
were made immediately after ultrafiltration, a maneuver that
would tend to obliterate predialysis alterations in preload. Our
study design avoided the pitfalls that have clouded interpreta-
tion of previous efforts at examining the hemodynamic conse-
quences of improvement of anemia in dialysis patients. Specif-
ically, we tightly controlled post-dialysis volume, biochemical
milieu and drugs that might have cardiovascular effects. The
current study is the first to use a load and heart rate independent
measurement of left ventricular contractility.
At any moment in time, overall left ventricular systolic
performance reflects the net effects of preload, afterload, heart
rate and contractility. Isolated increases in heart rate, preload
and contractility and a fall in afterload improve cardiac output
whereas changes of these variables in the opposite direction
diminish cardiac output. Thus, unless these hemodynamic
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Fig. 1. Values for arterial systolic and
diastolic blood pressures (BP) as well as body
weights obtained before and after
hemodialysis. Diagonal lines represent pre-
erythropoietin (rHuEPO) measurements;
hatched lines are post-rHuEPO.
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Fig. 2. Data for the left ventricular (LV) circumferential end-systolic
wall stress (g/cm2) versus the rate corrected velocity offiber shortening
(Vcf, circumferences/s) relation obtained from one of our study
patients. The pre-erythropoietin (rHuEPO) points are shown as circles,
the post-rHuEPO points by squares. Shaded points were acquired
under control conditions while open points were obtained during
afterload alteration with nitroprusside or methoxamine. The vertical
dashed line demonstrates the level of end-systolic wall stress that was
used for comparison of pre and post-rHuEPO data.
Patient Pre-EPO Post-EPO Delta
1 1.11 1.01 —0.100
2 0.87 0.79 —0.080
3 0.80 0.80 0.000
4 0.59 0.48 —0.113
5 0.81 0.74 —0.070
6 1.07 0.92 —0.153
7 0.91 0.71 —0.195
8 1.30 1.07 —0.231
9 1.16 1.14 —0.020
Mean 0.96 0.07 0.85 0.07a —0.11 o.03
parameters are carefully measured, statements about the spe-
cific cardiovascular mechanisms affecting global left ventricular
performance after correction of anemia may be inaccurate.
We have previously shown that myocardial contractility
varies directly with blood ionized calcium (Ca2) [22]. Predial-
ysis Ca2 has been shown to be 0.96 0.03 versus 1.19 0.03
mmol/liter in hemodialysis patients utilizing a 1.50 mmollliter
calcium dialysate [26]. This value compares to 1.34 mmol/liter
immediately after dialysis with a 1.75 mmol/liter calcium dialy-
sis bath [22]. If hemodynamic measurements are not made in
exactly the same phase of the interdialytic cycle, inter-study
differences in Ca2 can modify myocardial performance.
Drugs that alter heart rate, contractile state or sympathetic
tone can obscure or abolish hemodynamic changes that result
from correction of anemia with rHuEPO [21]. Even if there is
no change in drug regimen between pre- and post-rHuEPO
studies, the presence of such pharmacologic agents may pre-
vent the expression of responses that are mediated by the
sympathetic nervous system or by intrinsic changes in contrac-
0.00
—0.05
—0.25
tility. Many of the previous studies of the effect of rHuEPO on
the heart did not control for these drugs [6, 8—il, 13]. We
specifically prohibited the use of inotropic agents as well as beta
adrenoreceptor and calcium channel blocking drugs for at least
one week prior to each study.
A criticism of all studies that examine myocardial perfor-
mance in a time dependent fashion following therapy with
rHuEPO is that progression of myocardial disease from hyper-
tension or ischemia can confound changes that result from
correction of anemia. The relatively short study period (8 2
months) would not be expected to be associated with clinically
significant changes in cardiac performance in stable patients
with well controlled blood pressure. Furthermore, we excluded
from analysis patients who had developed symptomatic or
objective evidence of ischemic heart disease during the treat-
ment period. This allowed the study to remain focused on the
physiologic issues related to the correction of anemia. A
criticism of the current study is that only nine of the eighteen
patients met the stringent technical criteria for inclusion in the
analysis of Vcf and logically raises the question of bias. That
these nine patients did not differ from the group as a whole in
gender, race, age, etiology of renal disease, duration of hemo-
dialysis or use of antihypertensive drugs confirms lack of
segregation of a subpopulation of patients.
We, like others, have noted an increase in blood pressure in
about one third of dialysis patients after therapy with rHuEPO
[27]. Increases in whole blood viscosity and reversal of hypoxia
induced vasodilatation have been suggested as possible causes
of increases in blood pressure [27]. However, while a rise in
viscosity and systemic vascular resistance is a nearly universal
finding in patients whose anemia is corrected with rHuEPO, the
development of hypertension is not. It has been suggested that
the presence of a mismatch between increased TVR and re-
duced cardiac output identifies those who become hypertensive
[271. In our study, there was no correlation between changes in
cardiac output after rHuEPO and the development of hyperten-
sion.
What is the physiologic basis for the hemodynamic responses
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Fig. 3. Plot of the relationship between the change in hematocrit
(iHct) and change in left ventricular contractility (IVcf) in the nine
patients who underwent afterload manipulation with methoxamine or
nitroprusside. Correction of anemia was associated with a decrease in
LV contractile state.
Table 3. Rate corrected velocity of circumferential fiber shortening
(Vcf) (circ/sec) at a common level of afterload
a P = 0.003, post-EPO vs. pre-EPO
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to anemia? The hyperdynamic circulatory changes of anemia
are characterized by increased heart rate and cardiac output,
augmented myocardial contractility and a fall in systemic vas-
cular resistance. It is possible that anemia stimulates humerally-
mediated positive chronotropic and inotropic responses leading
to primary increases in left ventricular contractility, heart rate
and cardiac output. Alternatively, a reduction in systemic
vascular resistance from hypoxic vasodilatation and reduced
viscosity may cause a secondary enhancement of overall myo-
cardial performance. It is unlikely that this latter explanation
alone delineates the compensatory cardiovascular responses to
anemia since it would not explain the enhanced contractile state
present prior to amelioration of anemia with rHuEPO.
Cardiovascular disease is the leading cause of death in
patients undergoing maintenance dialysis [28]. Pre-existing hy-
pertension and coronary atherosclerotic heart disease consti-
tute a major proportion of the cardiomyopathies of the renal
failure population [19, 20, 291. The contribution of arterio-
venous fistulas, intermittent volume overload and anemia to
progressive myocardial disease is not known with certainty.
However, our study shows that correction of anemia in patients
undergoing chronic dialysis results in a significant reduction in
two of the three major determinants of myocardial energy
demand (that is, heart rate and contractility) without altering
the third (that is, LV systolic load). This may favorably
influence the progression of heart disease in these patients.
Reversal of left ventricular hypertrophy after therapy with
rHuEPO has been demonstrated in several studies [10, 30]. In
the current investigation, there was no change in left ventricular
wall mass index. This may reflect the relatively short duration
of follow-up in our study patients. The potential benefits of
correction of the hyperdynamic circulatory state of anemia
must be balanced against the theoretical deleterious effects of
worsening of blood pressure control in some patients, higher
whole blood viscosity and increased systemic vascular resis-
tance. Whether rHuEPO ultimately will improve long-term
prognosis regarding cardiovascular disease in patients undergo-
ing long-term dialysis is not yet known.
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